143 related articles for article (PubMed ID: 3731637)
1. [An analysis of long-term L-dopa treatment on 122 cases of Parkinson's disease over 14 years--when should L-dopa therapy be initiated?].
Indo T; Takahashi A
Rinsho Shinkeigaku; 1986 Apr; 26(4):363-71. PubMed ID: 3731637
[No Abstract] [Full Text] [Related]
2. Long-term follow-up of early dopa treatment in Parkinson's disease.
Markham CH; Diamond SG
Ann Neurol; 1986 Apr; 19(4):365-72. PubMed ID: 3707088
[TBL] [Abstract][Full Text] [Related]
3. Parkinson's disease: progression and mortality in the L-DOPA era.
Di Rocco A; Molinari SP; Kollmeier B; Yahr MD
Adv Neurol; 1996; 69():3-11. PubMed ID: 8615142
[No Abstract] [Full Text] [Related]
4. Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease.
Lin JJ; Yueh KC; Lin SZ; Harn HJ; Liu JT
J Neurol Sci; 2007 Jan; 252(2):130-4. PubMed ID: 17196621
[TBL] [Abstract][Full Text] [Related]
5. [Multivariate analysis of the problems of long-term levodopa therapy in Parkinson's disease].
Nakamura Y; Yoshinaga J; Endo S; Hikiji A
Rinsho Shinkeigaku; 1997 Jun; 37(6):469-75. PubMed ID: 9366172
[TBL] [Abstract][Full Text] [Related]
6. [A clinical analysis of L-dopa induced dyskinesia treated by posteroventral pallidotomy for Parkinson's disease].
Zhao G; Li Y; Shao M; Ding Y
Zhonghua Wai Ke Za Zhi; 1999 Aug; 37(8):482-4. PubMed ID: 11829894
[TBL] [Abstract][Full Text] [Related]
7. L-dopa induced dyskinesias in asymmetrical parkinsonism.
Murphy MJ
Acta Neurol Latinoam; 1979; 25(1-2):47-52. PubMed ID: 583384
[TBL] [Abstract][Full Text] [Related]
8. Levodopa in the early treatment of Parkinson's disease.
Murata M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
[TBL] [Abstract][Full Text] [Related]
9. Response to L-dopa and evolution of motor fluctuations in the early phase of treatment of Parkinson's disease.
Shif M; Kempster PA
Clin Exp Neurol; 1994; 31():38-42. PubMed ID: 7586663
[TBL] [Abstract][Full Text] [Related]
10. [Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, HCL-benserazide, on Parkinson's disease-part I: clinical aspects (author's transl)].
Yokochi M; Kondo T; Hirayama K; Narabayashi H; Kuruma I
No To Shinkei; 1979 Mar; 31(3):295-304. PubMed ID: 444336
[No Abstract] [Full Text] [Related]
11. Treatment of Parkinson's disease: levodopa as the first choice.
Katzenschlager R; Lees AJ
J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
[TBL] [Abstract][Full Text] [Related]
12. Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy.
Mazzella L; Yahr MD; Marinelli L; Huang N; Moshier E; Di Rocco A
Parkinsonism Relat Disord; 2005 May; 11(3):151-5. PubMed ID: 15823479
[TBL] [Abstract][Full Text] [Related]
13. Disordered respiration as a levodopa-induced dyskinesia in Parkinson's disease.
Rice JE; Antic R; Thompson PD
Mov Disord; 2002 May; 17(3):524-7. PubMed ID: 12112201
[TBL] [Abstract][Full Text] [Related]
14. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W
Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079
[TBL] [Abstract][Full Text] [Related]
15. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years.
Hely MA; Morris JG; Reid WG; Trafficante R
Mov Disord; 2005 Feb; 20(2):190-9. PubMed ID: 15551331
[TBL] [Abstract][Full Text] [Related]
16. Clinical aspects of motor fluctuations in Parkinson's disease.
Poewe WH
Neurology; 1994 Jul; 44(7 Suppl 6):S6-9. PubMed ID: 8047260
[TBL] [Abstract][Full Text] [Related]
17. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
[TBL] [Abstract][Full Text] [Related]
18. [Dyskinesia caused by L-DOPA].
Derkinderen P; Vidailhet M
Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S92-101. PubMed ID: 12690668
[TBL] [Abstract][Full Text] [Related]
19. [Aspects of long-term treatment with levodopa alone and levodopa combined with dopa decarboxylase inhibitors].
Cinca I; Serbănescu A; Tudorache B
Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1982; 27(4):261-70. PubMed ID: 6222452
[No Abstract] [Full Text] [Related]
20. Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease.
Segovia G; Mora F; Crossman AR; Brotchie JM
Mov Disord; 2003 Feb; 18(2):138-49. PubMed ID: 12539206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
